具有减少脱靶效应的5-羟色胺释放剂
该研究在临床前模型中证实,某些环取代卡西酮的S-对映体优先释放5-羟色胺,并表现出5-HT相关行为效应;先导化合物不引起显著多巴胺释放,且对囊泡单胺转运体和5-HT2B受体脱靶活性降低,提示低滥用潜力和低不良事件风险。
要点
- S-对映体卡西酮类化合物在离体和体内优先释放5-HT。
- 先导化合物不引起显著多巴胺释放,提示低滥用潜力。
- 对VMAT和5-HT2B受体脱靶活性降低,提示低不良事件风险。
核心结论
- 这些5-HT释放剂先导化合物可能用于治疗升高5-HT有益的疾病。
研究设计与样本
- 临床前研究,评估环取代卡西酮S-对映体的离体和体内5-HT释放及行为效应。
主要发现
- S-对映体在离体和体内优先释放5-HT,并在临床前行为模型中产生5-HT相关效应。
- 先导卡西酮化合物不引起显著多巴胺释放。
- 先导化合物对囊泡单胺转运体和5-HT2B受体的脱靶活性降低。
临床怎么用
- 提示这些化合物可作为治疗抑郁和焦虑相关障碍的候选药物进一步开发。
局限性
- 证据来自临床前研究,尚未在人体中验证疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Increasing extracellular levels of serotonin (5-HT) in the brain ameliorates symptoms of depression and anxiety-related disorders, e.g., social phobias and post-traumatic stress disorder. Recent evidence from preclinical and clinical studies established the therapeutic potential of drugs inducing the release of 5-HT via the 5-HT-transporter. Nevertheless, current 5-HT releasing compounds under clinical investigation carry the risk for abuse and deleterious side effects. Here, we demonstrate that S-enantiomers of certain ring-substituted cathinones show preference for the release of 5-HT ex vivo and in vivo, and exert 5-HT-associated effects in preclinical behavioral models. Importantly, the lead cathinone compounds (1) do not induce substantial dopamine release and (2) display reduced off-target activity at vesicular monoamine transporters and 5-HT2B-receptors, indicative of low abuse-liability and low potential for adverse events. Taken together, our findings identify these agents as lead compounds that may prove useful for the treatment of disorders where elevation of 5-HT has proven beneficial.
引用
- Mayer FP, Niello M, Cintulova D, et al. Serotonin-releasing agents with reduced off-target effects. Mol Psychiatry. 2022. PMID: 36352123. doi:10.1038/s41380-022-01843-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。